SG Americas Securities LLC Makes New Investment in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

SG Americas Securities LLC purchased a new stake in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 23,586 shares of the company’s stock, valued at approximately $572,000.

Other hedge funds have also added to or reduced their stakes in the company. Campbell & CO Investment Adviser LLC bought a new position in shares of Centessa Pharmaceuticals during the 2nd quarter valued at about $218,000. American Century Companies Inc. raised its holdings in Centessa Pharmaceuticals by 3.5% during the 2nd quarter. American Century Companies Inc. now owns 1,130,708 shares of the company’s stock worth $14,858,000 after buying an additional 37,954 shares during the period. Bollard Group LLC bought a new position in Centessa Pharmaceuticals in the second quarter valued at approximately $1,319,000. Ensign Peak Advisors Inc lifted its stake in Centessa Pharmaceuticals by 27.8% in the second quarter. Ensign Peak Advisors Inc now owns 559,744 shares of the company’s stock valued at $7,355,000 after buying an additional 121,611 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of Centessa Pharmaceuticals in the second quarter valued at approximately $725,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Insiders Place Their Bets

In other news, insider Mario Alberto Accardi sold 10,000 shares of the business’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $30.00, for a total transaction of $300,000.00. Following the transaction, the insider directly owned 178,801 shares in the company, valued at $5,364,030. The trade was a 5.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CTO Tia L. Bush sold 40,000 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $26.00, for a total transaction of $1,040,000.00. Following the completion of the sale, the chief technology officer directly owned 121,503 shares in the company, valued at approximately $3,159,078. The trade was a 24.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 58,000 shares of company stock worth $1,540,000. 7.09% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. B. Riley boosted their price objective on shares of Centessa Pharmaceuticals from $33.00 to $42.00 and gave the company a “buy” rating in a research report on Monday, December 1st. Oppenheimer boosted their price target on Centessa Pharmaceuticals from $40.00 to $62.00 and gave the company an “outperform” rating in a report on Wednesday, December 10th. Wall Street Zen upgraded Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, October 27th. Piper Sandler restated an “overweight” rating on shares of Centessa Pharmaceuticals in a research note on Friday, January 16th. Finally, Truist Financial raised their price target on shares of Centessa Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Centessa Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $38.00.

Centessa Pharmaceuticals Stock Performance

CNTA opened at $25.27 on Friday. The business’s 50-day simple moving average is $25.81 and its 200 day simple moving average is $21.99. Centessa Pharmaceuticals PLC Sponsored ADR has a 52-week low of $9.60 and a 52-week high of $30.58. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56. The firm has a market capitalization of $3.40 billion, a PE ratio of -13.81 and a beta of 1.56.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.02). As a group, sell-side analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current fiscal year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.